The neointimal response to stents eluting Tacrolimus from a degradable coating depends on the balance between polymer degradation and drug release

EuroIntervention

Volumn 4, Issue 1, 2008, Pages 139-147

  Van Beusekom, Heleen ^a   Sorop, Oana ^a   Weymaere, Michael ^a   Duncker, Dirk ^a   Van Der Giessen, Willem ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Biocompatibility; Coronary angioplasty; Drug eluting stent; Endothelium; Porcine model; Tacrolimus

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; POLYGLACTIN; TACROLIMUS; BIOMATERIAL; ELASTIN; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; METAL; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BIODEGRADABILITY; BLOOD VESSEL INJURY; CORONARY ARTERY; DRUG RELEASE; FOLLOW UP; MATERIAL COATING; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG ELUTING STENT; IMMUNOHISTOCHEMISTRY; INJURY; INTIMA; METABOLISM; MINIPIG; PATHOLOGY; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY; TUNICA MEDIA; VASCULAR ENDOTHELIUM; VASCULITIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ELASTIN; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; METALS; NITRIC OXIDE SYNTHASE TYPE III; POLYGLYCOLIC ACID; SUS SCROFA; SWINE; SWINE, MINIATURE; TACROLIMUS; TUNICA INTIMA; TUNICA MEDIA; VASCULITIS;

EID: 59249104630     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV4I1A22     Document Type: Article

References (24)

1. Ong AT, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT, Serruys PW. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Eur Heart J. 2006;27(24):2996-3003.
2. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45(7):1135-1141.
3. Daemen J, Serruys PW. Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation. 2007;116(3):316-328.
4. Wentzel JJ, Krams R, Schuurbiers JC, Oomen JA, Kloet J, van Der Giessen WJ, Serruys PW, Slager CJ. Relationship between neointimal thickness and shear stress after Wallstent implantation in human coronary arteries. Circulation. 2001;103(13):1740-1745.
5. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40(9):1249-1255.
6. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80(3 Pt 2):S40-45.
7. St Peter SD, Moss AA, Mulligan DC. Effects of tacrolimus on ischemia-reperfusion injury. Liver Transpl. 2003;9(2):105-116.
8. van Beusekom HM, Whelan DM, Hofma SH, Krabbendam SC, van Hinsbergh VW, Verdouw PD, van der Giessen WJ. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol. 1998;32(4):1109-1117.
9. van Der Giessen WJ, Regar E, Harteveld MS, Coen VL, Bhagwandien R, Au A, Levendag PC, Ligthart J, Serruys PW, den Boer A, Verdouw PD, Boersma E, Hu T, van Beusekom HM. “Edge Effect” of (32)p radioactive stents is caused by the combination of chronic stent injury and radioactive dose falloff. Circulation. 2001;104(18):2236-2241.
10. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, van Beusekom HM. Biocompatibility of phos-phorylcholine coated stents in normal porcine coronary arteries. Heart. 2000;83(3):338-345.
11. Derkx P, Nigg AL, Bosman FT, Birkenhager-Frenkel DH, Houtsmuller AB, Pols HA, van Leeuwen JP. Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacry-late-embedded adult human bone in combination with histomorphome-try. Bone. 1998;22(4):367-373.
12. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267-274.
13. Grayson AC, Voskerician G, Lynn A, Anderson JM, Cima MJ, Langer R. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J Biomater Sci Polym Ed. 2004;15(10):1281-1304.
14. van Beusekom HM, Saia F, Zindler JD, Lemos PA, Swager-Ten Hoor SL, van Leeuwen MA, de Feijter PJ, Serruys PW, van der Giessen WJ. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J. 2007;28(8):974-979.
15. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46(2):231-236.
16. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayedhealingandlatethromboticrisk.JAmCollCardiol.2006;48(1):193-202.
17. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27(2):166-170.
18. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch H, Grunenfelder J, Zund G, Tanner FC, Luscher TF. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2006;48(6):286-292.
19. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr., Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94(7):1690-1697.
20. Hofma SH, Whelan DM, van Beusekom HM, Verdouw PD, van der Giessen WJ. Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur Heart J. 1998;19(4):601-609.
21. Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, Fischer A, Wnendt S, Erbel R. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv. 2003;60(3):399-407.
22. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A, Haberstroh J, Wnendt S, Virmani R, Hehrlein C. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv. 2005;64(1):85-90.
23. Scheller B, Grandt A, Wnendt S, Lorenz G, Bohm M, Nickenig G. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol. 2005;94(7):445-452.
24. Huang Y, Salu K, Wang L, Liu X, Li S, Lorenz G, Wnendt S, Verbeken E, Bosmans J, Van de Werf F, De Scheerder I. Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model. J Invasive Cardiol. 2005;17(3):142-148.